“In his presidential address on Monday at DDW®, AGA President Timothy Wang, MD, AGAF, reviewed AGA’s accomplishments and priorities under his leadership over the past year, highlighting several new tools that help AGA members address changes to the GI practice environment.
Clostridium difficile colitis does not happen in a vacuum. When, why and how C. diff populations explode and cause colitis is the result of a complex interplay among bacteria, human host, the gut microbiome and the environment.
CRC screening guidelines vary around the world. The U.S. is one of the only countries, for example, that relies heavily on colonoscopies for CRC screening in average-risk populations. Other countries tend to rely on less expensive and less invasive screening technologies for average-risk screening.
Two new strategies are emerging to treat GI and other cancers — engineered T cells and immune checkpoint blockade treatments.
Physician innovators must be determined, entrepreneurial to get a medical device or technology to market
Have an idea for a new medical device, technology or service? Getting it to market is a complex, time-consuming process that requires analytical and management skills, great communication, collaboration and leadership, according to Virender Sharma, MD, AGAF, who shared lessons he’s learned as a physician innovator on Saturday at DDW® during a session sponsored by the AGA Center for GI Innovation and Technology.
What you learned last year about the treatment of IBD is already out of date.
Obese patients need a multidisciplinary team to help them achieve a healthy weight, and no one is better suited to lead the team than a gastroenterologist.
Can viral hepatitis be eliminated? That’s the key question to be addressed Monday at the annual AGA Emmet B. Keeffe Symposium, Prevention of Viral Hepatitis Through Vaccination: Done or Just Getting Started?
Siddharth Singh, MD
Assistant Professor of Medicine, Division of Gastroenterology, University of California, San Diego
Gastroenterologists treating patients with celiac disease face a difficult choice when deciding whether to biopsy. New European guidelines for pediatric patients suggest that serum markers and genetics are sufficient to confirm a diagnosis in many patients. U.S. guidelines still generally call for a biopsy to confirm the diagnosis.